Sensus Healthcare, Inc. (NASDAQ:SRTS) CEO Joseph C. Sardano Buys 10,000 Shares

Sensus Healthcare, Inc. (NASDAQ:SRTS) CEO Joseph C. Sardano bought 10,000 shares of Sensus Healthcare stock in a transaction dated Thursday, September 14th. The stock was purchased at an average cost of $2.88 per share, with a total value of $28,800.00. Following the completion of the acquisition, the chief executive officer now directly owns 1,175,293 shares in the company, valued at approximately $3,384,843.84. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Sensus Healthcare Stock Up 3.3 %

NASDAQ SRTS opened at $2.82 on Tuesday. The business’s 50-day moving average price is $3.10 and its 200 day moving average price is $3.67. The firm has a market cap of $46.22 million, a P/E ratio of 20.14 and a beta of 0.67. Sensus Healthcare, Inc. has a 52-week low of $2.29 and a 52-week high of $15.17.

Sensus Healthcare (NASDAQ:SRTS) last released its earnings results on Thursday, August 3rd. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.03. The business had revenue of $4.53 million for the quarter, compared to analyst estimates of $4.90 million. Sensus Healthcare had a return on equity of 5.09% and a net margin of 7.94%. As a group, analysts anticipate that Sensus Healthcare, Inc. will post -0.11 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in SRTS. O Shaughnessy Asset Management LLC boosted its stake in shares of Sensus Healthcare by 10.6% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 27,022 shares of the company’s stock valued at $201,000 after buying an additional 2,599 shares in the last quarter. Rockefeller Capital Management L.P. increased its holdings in shares of Sensus Healthcare by 75.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 7,000 shares of the company’s stock valued at $51,000 after purchasing an additional 3,000 shares in the last quarter. Northern Trust Corp increased its holdings in shares of Sensus Healthcare by 15.0% in the 1st quarter. Northern Trust Corp now owns 24,602 shares of the company’s stock valued at $249,000 after purchasing an additional 3,203 shares in the last quarter. State Street Corp lifted its stake in shares of Sensus Healthcare by 8.9% in the first quarter. State Street Corp now owns 46,052 shares of the company’s stock valued at $466,000 after purchasing an additional 3,765 shares during the period. Finally, Jane Street Group LLC boosted its holdings in Sensus Healthcare by 29.9% during the second quarter. Jane Street Group LLC now owns 17,167 shares of the company’s stock worth $132,000 after buying an additional 3,948 shares in the last quarter. 20.56% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright decreased their price objective on Sensus Healthcare from $10.00 to $8.00 and set a “buy” rating for the company in a report on Monday, August 7th.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.